Key Highlights

  • EVE Health Group (ASX:EVE), Noxopharm (ASX:NOX) and Doctor Care Anywhere (ASX:DOC) touched 52-week lows during the 26 October 2026 session.
  • EVE's FY26 Revenue fell 33.53% to $1,153,101, and Noxopharm's cash was $293,573 at 30 June 2026.
  • Doctor Care Anywhere reported EBITDA of £4.9 million and cash of £7.7 million for the 12 months to 30 June 2026.

EVE Health Group Limited (ASX:EVE) traded at $0.011, down 26.67%, Noxopharm Limited (ASX:NOX) traded at $0.049, down 10.91%, and Doctor Care Anywhere Group PLC (ASX:DOC) traded at $0.10, down 9.09%, after each touched a 52-week low during the Trading session on 26 October 2026. EVE develops wellness and pharmaceutical products, Noxopharm is a clinical-stage biotech and Doctor Care Anywhere is a UK virtual healthcare provider whose CDIs trade on the ASX.

EVE Health Group: Results and ASX Reply

EVE's Appendix 4E, released on 31 August 2026, reported revenue down 33.53% to $1,153,101 and a loss attributable to members up 19.67% to $1,890,753, with no dividends. Net tangible assets per security were $0.0031.

On 26 October 2026 the company replied to an ASX price and Volume query, saying it holds no undisclosed information and understands a Shareholder formerly associated with it may be disposing of their holding.

The Appendix 4E also gives net tangible assets of $0.0031 per ordinary security, compared with $0.0023 a year earlier, and confirms that no dividends were paid, declared or determined. Commentary on the results sits in the 2026 Annual Report accompanying the announcement.

Noxopharm: Annual Report Released on 16 October 2026

Noxopharm's annual report records a Phase I trial of SOF-SKN, a topical candidate for cutaneous lupus, that demonstrated safety and tolerability in healthy volunteers. An extension study will give the drug to cutaneous lupus patients for the first time.

The Cash Flow Statement shows cash of $293,573 at 30 June 2026, down from $1,554,174, and R&D tax rebate receipts of $2,806,583.

The company says it recognises a refundable tax offset equal to 43.5% of eligible R&D expenditure under the Research and Development Tax Incentive, and the annual report discusses proposed changes to that scheme. The report describes its work as having been published in a respected journal.

Doctor Care Anywhere: Strategy Update Dated 23 October 2026

The company's investor primer reports EBITDA of £4.9 million for the twelve months to 30 June 2026 and cash of £7.7 million, up 60%. Subscription revenue rose to 10.8% of the first-half total, helped by a weight-management platform bought in May 2026 for £0.9 million. About 89% of H1 FY26 revenue came from insurance, down from 93% in FY2025.

The primer estimates the UK telehealth market at about £6.3 billion, puts FY2025 revenue of £38.0 million at roughly 0.6% of it, and notes a Partnership with Ramsay Health Care UK opening a self-pay channel. The weight-management Business contributed £0.9 million of revenue in its first 54 days at approximately breakeven.

About the Companies

EVE Health Group Limited (ASX:EVE): EVE Health Group is an Australian health company developing and commercialising wellness and pharmaceutical products through its subsidiaries Meluka Australia and Nextract, sold across retail, pharmacy and clinical channels.

Noxopharm Limited (ASX:NOX): Noxopharm is a Sydney-based clinical-stage biotech developing targeted therapies for chronic inflammation, autoimmune diseases and cancer on its Sofra platform. Its lead asset, SOF-SKN, is a topical therapy for cutaneous lupus erythematosus.

Doctor Care Anywhere Group Plc (ASX:DOC): Doctor Care Anywhere is a UK virtual healthcare provider delivering GP, mental health, physiotherapy and health assessment services, paid for by private medical insurers, employers and healthcare providers. Its CDIs trade on the ASX under DOC.

Risks Across the Three Companies

EVE reports lower revenue and a larger loss. Noxopharm's cash fell and its next steps depend on clinical progress and the R&D tax scheme. Doctor Care Anywhere's revenue is concentrated in one insurer relationship and its regulator rating is Requires Improvement.

Catalysts on Investors' Radar

Noxopharm's cutaneous lupus extension study, Doctor Care Anywhere's reporting on subscription share and consultations, and EVE's next periodic reports are the items identified.

Additional details give context to each filing. Doctor Care Anywhere reports labour cost down 4.9% against revenue growth of 6.3%, free cash flow of £1.5 million and a partnership with Ramsay Health Care UK. Noxopharm recognises a refundable tax offset of 43.5% of eligible R&D spending and received $2,806,583 of rebates in the year. EVE's net loss attributable to members rose 19.67% to $1,890,753, and the company reported no associates or joint ventures.

Final Perspective

The three healthcare companies touched 52-week lows in one session, with a results filing, an annual report and a strategy document each providing the latest disclosed figures.